AstraZeneca’s struggle, China’s fresh restrictions on big techs may weigh on sentiment
|The Wall Street Journal (WSJ) came out with two different news pieces that cited challenges for late Thursday’s recovery in the market sentiment.
Among them, chatters over AstraZeneca’s struggle to collect data for another regulatory stamp from the US Food and Drug Administration (FDA) gains major attention amid the first death, in Canada, due to the blood clotting issues after the usage of the vaccine.
“An FDA signoff could boost global acceptance of the drugmaker’s shot, health and drug-industry experts say. But some said that if fresh doubts were to surface in an FDA review, that could undermine public perceptions of the vaccine,” said the WSJ.
On the other hand, China’s latest curbs on the big technology companies and payment processors to use data raised doubts that the world’s second-largest economy eyes more domestic growth than its previous push towards globalization.
While detailing the issue, WSJ stated, “Thursday, China’s central bank and other regulators ordered 13 firms, including many of the biggest names in the technology sector, to adhere to much tighter regulation of their data and lending practices.” The news added, “Their aim, say analysts, is to curb a revolutionary business model that let China’s Big Tech develop and use powerful payment apps and other information about hundreds of millions of users.”
FX implications
The news seems to exert downside pressure on the S&P 500 Futures, currently unchanged around 4,200, as the stock derivative fails to replicate its upbeat performance on Wall Street.
Read: Wall Street Close: Mildly bid on upbeat earnings, US GDP, S&P 500 refreshes record top
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.